Gastroesophageal Reflux
Conditions
Keywords
Gastroesophageal Reflux, Gastroesophageal Reflux Disease, Pantoprazole
Brief summary
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. GERD is one of the most common medical disorders, with estimates of up to 50% of adults reporting symptoms related to gastric reflux. Proton pump inhibitors (PPI) such as pantoprazole can relieve symptoms of GERD in a large proportion of patients. When refluxed stomach acidic content touches the lining of the esophagus, it causes a burning sensation in the chest or throat. This sensation is often referred to as heartburn. Some patients have symptoms of GERD without visible destruction of the tissue surface (no visible changes by endoscopic examination). The aim of the study is to evaluate the effect of pantoprazole on the complete remission of GERD. Complete remission is defined as endoscopically confirmed healing and symptom relief after a maximum of 12-week treatment period. Pantoprazole will be administered once daily in the morning. Endoscopy will be performed at the start of the study, and then as required after 4, 8, or 12 weeks. The study will provide further data on safety and tolerability of pantoprazole.
Interventions
DRUGPantoprazole
Sponsors
Takeda
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: * Outpatients * Reflux disease-related symptoms for at least 12 weeks, which need not be consecutive, in the previous 12 months or endoscopically confirmed reflux esophagitis grade A to D, according to LA-classification Main
Exclusion criteria
* Regular intake of systemic glucocorticosteroids, NSAIDs including COX-2 inhibitors on \>3 consecutive days per week within the previous 28 days; exception: regular intake of acetylsalicylic acid up to a daily dose of 150 mg/day * Intake of PPIs (proton pump inhibitor) during the last 10 days, of histamine 2-receptor antagonists or prokinetics during the last 5 days, intake of sucralfate during the last 2 days before the start of the study * Intake of PPIs in combination with antibiotics for eradication of H. pylori during the last 28 days prior to study start * Eradication of H. pylori during the last 28 days prior to study start * Acute peptic ulcer and/or ulcer complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete reflux disease remission rate after 8 weeks of treatment defined as symptom relief assessed by reflux questionnaire (ReQuest Trademark) and endoscopically confirmed healing. | — |
Secondary
| Measure | Time frame |
|---|---|
| time to reach first complete remission | — |
| time to reach sustained complete remission | — |
| time to reach first symptom relief that is based on the pre-defined GERD symptoms threshold of the reflux questionnaire | — |
| average symptom load above pre-defined GERD symptoms threshold | — |
| relief rates from reflux disease related complaints after 4, 8 and 12 weeks | — |
| complete reflux disease remission rates after 4, 8, and 12 weeks | — |
| symptom relief rates after 4, 8 and 12 weeks | — |
| influence of the H. pylori status on the complete reflux disease remission rate | — |
| influence of the H. pylori status on the symptom relief rates | — |
| influence of the H. pylori status on the endoscopically confirmed healing rates. | — |
| endoscopically confirmed healing rates after 4, 8, and 12 weeks | — |
Countries
Austria, Germany, Hungary, Poland
Outcome results
None listed